Skip to main content

Peer Review reports

From: A real-world study of Afatinib plus ramucirumab in treatment-naïve, EGFR-mutated, non–small cell lung cancer

Original Submission
13 Aug 2022 Submitted Original manuscript
27 Sep 2022 Reviewed Reviewer Report
28 Sep 2022 Reviewed Reviewer Report
2 Oct 2022 Reviewed Reviewer Report
3 Nov 2022 Author responded Author comments - Yao-Kuang Wu
Resubmission - Version 2
3 Nov 2022 Submitted Manuscript version 2
7 Nov 2022 Author responded Author comments - Yao-Kuang Wu
Resubmission - Version 3
7 Nov 2022 Submitted Manuscript version 3
9 Nov 2022 Reviewed Reviewer Report
10 Nov 2022 Reviewed Reviewer Report
20 Nov 2022 Reviewed Reviewer Report
24 Nov 2022 Reviewed Reviewer Report
8 Dec 2022 Reviewed Reviewer Report
7 Jan 2023 Author responded Author comments - Yao-Kuang Wu
Resubmission - Version 4
7 Jan 2023 Submitted Manuscript version 4
1 Feb 2023 Author responded Author comments - Yao-Kuang Wu
Resubmission - Version 5
1 Feb 2023 Submitted Manuscript version 5
2 Feb 2023 Author responded Author comments - Yao-Kuang Wu
Resubmission - Version 6
2 Feb 2023 Submitted Manuscript version 6
3 Feb 2023 Author responded Author comments - Yao-Kuang Wu
Resubmission - Version 7
3 Feb 2023 Submitted Manuscript version 7
5 Feb 2023 Author responded Author comments - Yao-Kuang Wu
Resubmission - Version 8
5 Feb 2023 Submitted Manuscript version 8
21 Feb 2023 Reviewed Reviewer Report
28 Feb 2023 Reviewed Reviewer Report
Resubmission - Version 9
Submitted Manuscript version 9
Publishing
2 May 2023 Editorially accepted
8 May 2023 Article published 10.1186/s12885-023-10909-z

You can find further information about peer review here.

Back to article page